Targeting the NF-κB Pathway in Cancer Therapy

Surgical Oncology Clinics of North America

Volumn 22, Issue 4, 2013, Pages 705-746

  Erstad, Derek J ^a   Cusack, James C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Apoptosis; Chemoresistance; IKK inhibitor; NF B inhibitor; Radioresistance; Targeting NF B

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ANTIOXIDANT; BENDAMUSTINE; BIOLOGICAL PRODUCT; BORTEZOMIB; CAMPTOTHECIN; CAPECITABINE; CAPSAICIN; CARBOPLATIN; CISPLATIN; CURCUMIN; DEXAMETHASONE; DOXORUBICIN; E1A PROTEIN; EPIRUBICIN; ETOPOSIDE; GEFITINIB; GEMCITABINE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; PROTEASOME INHIBITOR; RESVERATROL; SALAZOSULFAPYRIDINE; SIMVASTATIN; UNINDEXED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER GROWTH; CANCER PREVENTION; CANCER RESISTANCE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; LEUKEMIA; LIVER TOXICITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MULTIPLE CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE DISEASE; MYELOMA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW; RHEUMATOID ARTHRITIS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR ESCAPE; TUMOR PROMOTION; ULCERATIVE COLITIS; VIRAL GENE DELIVERY SYSTEM;

APOPTOSIS; CHEMORESISTANCE; IKK INHIBITOR; NF-ΚB INHIBITOR; RADIORESISTANCE; TARGETING NF-ΚB;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84883560456     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.06.011     Document Type: Review

References (316)

1. Wang X.W., Tan N.S., Ho B., et al. Evidence for the ancient origin of the NF-kappaB/IkappaB cascade: its archaic role in pathogen infection and immunity. Proc Natl Acad Sci USA 2006, 103:4204-4209.
2. Urban M.B., Schreck R., Baeuerle P.A. NF-kappa B contacts DNA by a heterodimer of the p50 and p65 subunit. EMBO J 1991, 10:1817-1825.
3. Baeuerle P.A., Baltimore D. Ikappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 1988, 242:540-546.
4. Yamazaki S., Muta T., Takeshige K. Anovel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. JBiol Chem 2001, 276:27657-27662.
5. Perkins N.D., Schmid R.M., Duckett C.S., et al. Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA 1992, 89:1529-1533.
6. Lernbecher T., Muller U., Wirth T. Distinct NF-kappa B/Rel transcription factors are responsible for tissue-specific and inducible gene activation. Nature 1993, 365:767-770.
7. Lai J.H., Horvath G., Subleski J., et al. RelA is a potent transcriptional activator of the CD28 response element within the interleukin 2 promoter. Mol Cell Biol 1995, 15:4260-4271.
8. Beg A.A., Sha W.C., Bronson R.T., et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995, 376:167-170.
9. Ivanov V.N., Lee R.K., Podack E.R., et al. Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-kappa B. Oncogene 1997, 14:2455-2464.
10. Schiemann B., Gommerman J.L., Vora K., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
11. Pomerantz J.L., Baltimore D. Two pathways to NF-kappaB. Mol Cell 2002, 10:693-695.
12. Senftleben U., Cao Y., Xiao G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001, 293:1495-1499.
13. May M.J., D'Acquisto F., Madge L.A., et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000, 289:1550-1554.
14. Palombella V.J., Rando O.J., Goldberg A.L., et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
15. Ghosh S., Baltimore D. Activation invitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 1990, 344:678-682.
16. Chiao P.J., Miyamoto S., Verma I.M. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 1994, 91:28-32.
17. Woronicz J.D., Gao X., Cao Z., et al. IkappaB kinase-beta: NF-kappaB activation and complex formation with IkappaB kinase-alpha and NIK. Science 1997, 278:866-869.
18. Zhong H., Voll R.E., Ghosh S. Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998, 1:661-671.
19. Joo J.H., Jetten A.M. NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. JBiol Chem 2008, 283:16391-16399.
20. Hoberg J.E., Popko A.E., Ramsey C.S., et al. IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300. Mol Cell Biol 2006, 26:457-471.
21. Grimes C.A., Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. JNeurochem 2001, 78:1219-1232.
22. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta 2010, 1805:167-180.
23. Lawrence T., Willoughby D.A., Gilroy D.W. Anti-inflammatory lipid mediators and insights into the resolution of inflammation. Nat Rev Immunol 2002, 2:787-795.
24. Ito C.Y., Kazantsev A.G., Baldwin A.S. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res 1994, 22:3787-3792.
25. Collett G.P., Campbell F.C. Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006, 27:1285-1291.
26. Rodrigues L., Filipe J., Seldon M.P., et al. Termination of NF-kappaB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase. EMBO J 2009, 28:1283-1295.
27. de Bie P., van de Sluis B., Burstein E., et al. Characterization of COMMD protein-protein interactions in NF-kappaB signalling. Biochem J 2006, 398:63-71.
28. Udalova I.A., Richardson A., Denys A., et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol 2000, 20:9113-9119.
29. Yang J., Fan G.H., Wadzinski B.E., et al. Protein phosphatase 2A interacts with and directly dephosphorylates RelA. JBiol Chem 2001, 276:47828-47833.
30. Arsura M., Wu M., Sonenshein G.E. TGF beta 1 inhibits NF-kappa B/Rel activity inducing apoptosis of B cells: transcriptional activation of I kappa B alpha. Immunity 1996, 5:31-40.
31. Ballard D.W., Walker W.H., Doerre S., et al. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell 1990, 63:803-814.
32. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
33. Greten F.R., Eckmann L., Greten T.F., et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
34. Pikarsky E., Porat R.M., Stein I., et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
35. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4:71-78.
36. Bobrovnikova-Marjon E.V., Marjon P.L., Barbash O., et al. Expression of angiogenic factors vascular endothelial growth factor and interleukin-8/CXCL8 is highly responsive to ambient glutamine availability: role of nuclear factor-kappaB and activating protein-1. Cancer Res 2004, 64:4858-4869.
37. Martin D., Galisteo R., Gutkind J.S. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. JBiol Chem 2009, 284:6038-6042.
38. Wu W., Pan C., Meng K., et al. Hypoxia activates heparanase expression in an NF-kappaB dependent manner. Oncol Rep 2010, 23:255-261.
39. Bond M., Fabunmi R.P., Baker A.H., et al. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998, 435:29-34.
40. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. JBiol Chem 1994, 269:4705-4708.
41. Tomonaga M., Hashimoto N., Tokunaga F., et al. Activation of nuclear factor-kappa B by linear ubiquitin chain assembly complex contributes to lung metastasis of osteosarcoma cells. Int J Oncol 2012, 40:409-417.
42. Sasaki N., Morisaki T., Hashizume K., et al. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001, 7:4136-4142.
43. Kleinberg L., Dong H.P., Holth A., et al. Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma. Hum Pathol 2009, 40:795-806.
44. Harhaj E.W., Good L., Xiao G., et al. Gene expression profiles in HTLV-I-immortalized T cells: deregulated expression of genes involved in apoptosis regulation. Oncogene 1999, 18:1341-1349.
45. Lamsoul I., Lodewick J., Lebrun S., et al. Exclusive ubiquitination and sumoylation on overlapping lysine residues mediate NF-kappaB activation by the human T-cell leukemia virus tax oncoprotein. Mol Cell Biol 2005, 25:10391-10406.
46. Lee D.F., Kuo H.P., Chen C.T., et al. IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell 2007, 130:440-455.
47. Hu M.C., Lee D.F., Xia W., et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237.
48. Lee S., Andrieu C., Saltel F., et al. IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation. Proc Natl Acad Sci USA 2004, 101:17416-17421.
49. Gantke T., Sriskantharajah S., Sadowski M., et al. IkappaB kinase regulation of the TPL-2/ERK MAPK pathway. Immunol Rev 2012, 246:168-182.
50. Reiley W., Zhang M., Wu X., et al. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol 2005, 25:3886-3895.
51. Mattioli I., Sebald A., Bucher C., et al. Transient and selective NF-kappa B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by Ikappa B kinase beta and controls the kinetics of p65 nuclear import. JImmunol 2004, 172:6336-6344.
52. Lamberti C., Lin K.M., Yamamoto Y., et al. Regulation of beta-catenin function by the IkappaB kinases. JBiol Chem 2001, 276:42276-42286.
53. Yamamoto Y., Verma U.N., Prajapati S., et al. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 2003, 423:655-659.
54. Zhao T., Yang L., Sun Q., et al. The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 2007, 8:592-600.
55. Lee D.F., Hung M.C. Advances in targeting IKK and IKK-related kinases for cancer therapy. Clin Cancer Res 2008, 14:5656-5662.
56. Stavrovskaya A.A. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc) 2000, 65:95-106.
57. Moncharmont C., Levy A., Gilormini M., et al. Targeting a cornerstone of radiation resistance: cancer stem cell. Cancer Lett 2012, 322:139-147.
58. Shen D.W., Fojo A., Chin J.E., et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986, 232:643-645.
59. Cusack J.C., Liu R., Baldwin A.S. NF- kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF- kappa B. Drug Resist Updat 1999, 2:271-273.
60. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5:297-309.
61. Brach M.A., Hass R., Sherman M.L., et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. JClin Invest 1991, 88:691-695.
62. Weldon C.B., Burow M.E., Rolfe K.W., et al. NF-kappa B-mediated chemoresistance in breast cancer cells. Surgery 2001, 130:143-150.
63. Arlt A., Vorndamm J., Muerkoster S., et al. Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 2002, 62:910-916.
64. Chen X., Shen B., Xia L., et al. Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 2002, 62:1213-1221.
65. Fan M., Ahmed K.M., Coleman M.C., et al. Nuclear factor-kappaB and manganese superoxide dismutase mediate adaptive radioresistance in low-dose irradiated mouse skin epithelial cells. Cancer Res 2007, 67:3220-3228.
66. Wang C.Y., Cusack J.C., Liu R., et al. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999, 5:412-417.
67. Cusack J.C., Liu R., Baldwin A.S. Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation. Cancer Res 2000, 60:2323-2330.
68. Patel N.M., Nozaki S., Shortle N.H., et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappaB is enhanced by IkappaBalpha super-repressor and parthenolide. Oncogene 2000, 19:4159-4169.
69. Munshi A., Kurland J.F., Nishikawa T., et al. Inhibition of constitutively activated nuclear factor-kappaB radiosensitizes human melanoma cells. Mol Cancer Ther 2004, 3:985-992.
70. Tergaonkar V., Pando M., Vafa O., et al. p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 2002, 1:493-503.
71. Bednarski B.K., Ding X., Coombe K., et al. Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther 2008, 7:1827-1835.
72. Janssens S., Tinel A., Lippens S., et al. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005, 123:1079-1092.
73. Grandage V.L., Gale R.E., Linch D.C., et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005, 19:586-594.
74. Notarbartolo M., Poma P., Perri D., et al. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005, 224:53-65.
75. Meinel F.G., Mandl-Weber S., Baumann P., et al. The novel, proteasome-independent NF-kappaB inhibitor V1810 induces apoptosis and cell cycle arrest in multiple myeloma and overcomes NF-kappaB-mediated drug resistance. Mol Cancer Ther 2010, 9:300-310.
76. Josson S., Xu Y., Fang F., et al. RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Oncogene 2006, 25:1554-1559.
77. Tonks N.K. Redox redux: revisiting PTPs and the control of cell signaling. Cell 2005, 121:667-670.
78. Shen H.M., Liu Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006, 40:928-939.
79. Fang I.M., Yang C.H., Yang C.M., et al. Linoleic acid-induced expression of inducible nitric oxide synthase and cyclooxygenase II via p42/44 mitogen-activated protein kinase and nuclear factor-kappaB pathway in retinal pigment epithelial cells. Exp Eye Res 2007, 85:667-677.
80. Delhalle S., Deregowski V., Benoit V., et al. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 2002, 21:3917-3924.
81. Epinat J.C., Gilmore T.D. Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway. Oncogene 1999, 18:6896-6909.
82. Hayakawa M., Miyashita H., Sakamoto I., et al. Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J 2003, 22:3356-3366.
83. Cho S., Urata Y., Iida T., et al. Glutathione downregulates the phosphorylation of Ikappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells. Biochem Biophys Res Commun 1998, 253:104-108.
84. Natarajan K., Singh S., Burke T.R., et al. Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B. Proc Natl Acad Sci USA 1996, 93:9090-9095.
85. Eytan E., Ganoth D., Armon T., et al. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci USA 1989, 86:7751-7755.
86. Tanaka K., Mizushima T., Saeki Y. The proteasome: molecular machinery and pathophysiological roles. Biol Chem 2012, 393:217-234.
87. Kisselev A.F., van der Linden W.A., Overkleeft H.S. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012, 19:99-115.
88. Yin D., Zhou H., Kumagai T., et al. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24:344-354.
89. Shah S.A., Potter M.W., McDade T.P., et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. JCell Biochem 2001, 82:110-122.
90. Coquelle A., Mouhamad S., Pequignot M.O., et al. Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells. Cell Death Differ 2006, 13:873-875.
91. Ling Y.H., Liebes L., Jiang J.D., et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003, 9:1145-1154.
92. Adams J. The proteasome as a novel target for the treatment of breast cancer. Breast Dis 2002, 15:61-70.
93. Williams S., Pettaway C., Song R., et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003, 2:835-843.
94. Russo S.M., Tepper J.E., Baldwin A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001, 50:183-193.
95. Amschler K., Schon M.P., Pletz N., et al. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways. JInvest Dermatol 2010, 130:1073-1086.
96. Awasthi N., Schwarz M.A., Schwarz R.E. Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer. Cancer Biol Ther 2010, 10:99-107.
97. Denlinger C.E., Rundall B.K., Keller M.D., et al. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 2004, 78:1207-1214. [discussion: 14].
98. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. JBiol Chem 2002, 277:16639-16647.
99. Obeng E.A., Carlson L.M., Gutman D.M., et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006, 107:4907-4916.
100. Yam C.H., Siu W.Y., Lau A., et al. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. JBiol Chem 2000, 275:3158-3167.
101. Sudakin V., Ganoth D., Dahan A., et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995, 6:185-197.
102. Diehl J.A., Zindy F., Sherr C.J. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997, 11:957-972.
103. Clurman B.E., Sheaff R.J., Thress K., et al. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996, 10:1979-1990.
104. Pagano M., Tam S.W., Theodoras A.M., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
105. Chen F., Zhang Z., Bower J., et al. Arsenite-induced Cdc25C degradation is through the KEN-box and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 2002, 99:1990-1995.
106. Scheffner M., Werness B.A., Huibregtse J.M., et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
107. Yang Y., Fang S., Jensen J.P., et al. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 2000, 288:874-877.
108. Gallastegui N., Beck P., Arciniega M., et al. Hydroxyureas as noncovalent proteasome inhibitors. Angew Chem Int Ed Engl 2012, 51:247-249.
109. Tan X., Osmulski P.A., Gaczynska M. Allosteric regulators of the proteasome: potential drugs and a novel approach for drug design. Curr Med Chem 2006, 13:155-165.
110. Nam S., Smith D.M., Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity invitro and invivo. JBiol Chem 2001, 276:13322-13330.
111. Chauhan D., Li G., Podar K., et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood 2004, 103:3158-3166.
112. Plummer S.M., Holloway K.A., Manson M.M., et al. Inhibition of cyclo-oxygenase 2expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999, 18:6013-6020.
113. Harris S.G., Padilla J., Koumas L., et al. Prostaglandins as modulators of immunity. Trends Immunol 2002, 23:144-150.
114. Ninomiya I., Nagai N., Oyama K., et al. Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum. Oncol Rep 2012, 28:777-784.
115. Amano H., Ito Y., Suzuki T., et al. Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci 2009, 100:2318-2324.
116. Chang S.H., Liu C.H., Conway R., et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004, 101:591-596.
117. Pai R., Soreghan B., Szabo I.L., et al. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002, 8:289-293.
118. Jain S., Chakraborty G., Raja R., et al. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008, 68:7750-7759.
119. Chen Q., Galleano M., Cederbaum A.I. Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1. JBiol Chem 1997, 272:14532-14541.
120. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
121. Palayoor S.T., Youmell M.Y., Calderwood S.K., et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999, 18:7389-7394.
122. Liao X., Lochhead P., Nishihara R., et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. NEngl J Med 2012, 367:1596-1606.
123. Wahl C., Liptay S., Adler G., et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. JClin Invest 1998, 101:1163-1174.
124. Weber C.K., Liptay S., Wirth T., et al. Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology 2000, 119:1209-1218.
125. Narang V.S., Pauletti G.M., Gout P.W., et al. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells. Anticancer Res 2003, 23:4571-4579.
126. Robe P.A., Bentires-Alj M., Bonif M., et al. Invitro and invivo activity of the nuclear factor-kappaB inhibitor sulfasalazine in human glioblastomas. Clin Cancer Res 2004, 10:5595-5603.
127. Ryan B.M., Russel M.G., Langholz E., et al. Aminosalicylates and colorectal cancer in IBD: a not-so bitter pill to swallow. Am J Gastroenterol 2003, 98:1682-1687.
128. Gout P.W., Simms C.R., Robertson M.C. Invitro studies on the lymphoma growth-inhibitory activity of sulfasalazine. Anticancer Drugs 2003, 14:21-29.
129. Habens F., Srinivasan N., Oakley F., et al. Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity. Apoptosis 2005, 10:481-491.
130. Linares V., Alonso V., Domingo J.L. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opin Drug Saf 2011, 10:253-263.
131. Chung W.J., Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. JNeurochem 2009, 110:182-193.
132. Muerkoster S., Arlt A., Witt M., et al. Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer. Int J Cancer 2003, 104:469-476.
133. Arlt A., Gehrz A., Muerkoster S., et al. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene 2003, 22:3243-3251.
134. Scheinman R.I., Gualberto A., Jewell C.M., et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995, 15:943-953.
135. McKay L.I., Cidlowski J.A. CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol 2000, 14:1222-1234.
136. Lu Y.S., Yeh P.Y., Chuang S.E., et al. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. JEndocrinol 2006, 188:311-319.
137. Wang H., Wang Y., Rayburn E.R., et al. Dexamethasone as a chemosensitizer for breast cancer chemotherapy: potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol 2007, 30:947-953.
138. Wang H., Li M., Rinehart J.J., et al. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: invivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res 2004, 10:1633-1644.
139. Hofmann T.G., Hehner S.P., Bacher S., et al. Various glucocorticoids differ in their ability to induce gene expression, apoptosis and to repress NF-kappaB-dependent transcription. FEBS Lett 1998, 441:441-446.
140. Nicholson L., Hall A.G., Redfern C.P., et al. NFkappaB modulators in a model of glucocorticoid resistant, childhood acute lymphoblastic leukemia. Leuk Res 2010, 34:1366-1373.
141. Oerlemans R., Vink J., Dijkmans B.A., et al. Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor alpha and glucocorticoid induced apoptosis. Ann Rheum Dis 2007, 66:1289-1295.
142. Chauhan D., Auclair D., Robinson E.K., et al. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene 2002, 21:1346-1358.
143. Bantel H., Domschke W., Schulze-Osthoff K., et al. Abnormal activation of transcription factor NF-kappaB involved in steroid resistance in chronic inflammatory bowel disease. Am J Gastroenterol 2000, 95:1845-1846.
144. Weichhart T., Haidinger M., Katholnig K., et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011, 117:4273-4283.
145. Gross K.L., Oakley R.H., Scoltock A.B., et al. Glucocorticoid receptor alpha isoform-selective regulation of antiapoptotic genes in osteosarcoma cells: a new mechanism for glucocorticoid resistance. Mol Endocrinol 2011, 25:1087-1099.
146. Schmidt S., Irving J.A., Minto L., et al. Glucocorticoid resistance in two key models of acute lymphoblastic leukemia occurs at the level of the glucocorticoid receptor. FASEB J 2006, 20:2600-2602.
147. Gamble C., McIntosh K., Scott R., et al. Inhibitory kappa B kinases as targets for pharmacological regulation. Br J Pharmacol 2012, 165:802-819.
148. Sessa C., Vigano L., Grasselli G., et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006, 42:171-178.
149. Godl K., Gruss O.J., Eickhoff J., et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005, 65:6919-6926.
150. Yemelyanov A., Gasparian A., Lindholm P., et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006, 25:387-398.
151. Cilloni D., Messa F., Arruga F., et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. Leukemia 2006, 20:61-67.
152. Wen D., Nong Y., Morgan J.G., et al. Aselective small molecule IkappaB kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. JPharmacol Exp Ther 2006, 317:989-1001.
153. Al-Katib A., Arnold A.A., Aboukameel A., et al. I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. Mol Cancer 2010, 9:228.
154. Meng X., Martinez M.A., Raymond-Stintz M.A., et al. IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts. Br J Haematol 2010, 148:487-490.
155. Garcia M.G., Alaniz L., Lopes E.C., et al. Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines. Leuk Res 2005, 29:1425-1434.
156. Juliana C., Fernandes-Alnemri T., Wu J., et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. JBiol Chem 2010, 285:9792-9802.
157. Lee H., Lin C.I., Liao J.J., et al. Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism. Am J Physiol Cell Physiol 2004, 287:C1657-C1666.
158. Lee J., Rhee M.H., Kim E., et al. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediators Inflamm 2012, 2012:416036.
159. Frelin C., Imbert V., Griessinger E., et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 2005, 105:804-811.
160. Meng Z., Lou S., Tan J., et al. Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of (131)I on the invivo management of differentiated thyroid cancer. Life Sci 2012, 91:1236-1241.
161. Ma X., Yang L., Xiao L., et al. Down-regulation of EBV-LMP1 radio-sensitizes nasal pharyngeal carcinoma cells via NF-kappaB regulated ATM expression. PLoS One 2011, 6:e24647.
162. O'Neill A.J., Prencipe M., Dowling C., et al. Characterisation and manipulationof docetaxel resistant prostate cancer cell lines. Mol Cancer 2011, 10:126.
163. Bavi P., Uddin S., Bu R., et al. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). JPathol 2011, 224:355-366.
164. Hu X., Janssen W.E., Moscinski L.C., et al. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res 2001, 61:6290-6296.
165. Sourbier C., Danilin S., Lindner V., et al. Targeting the nuclear factor-kappaB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007, 67:11668-11676.
166. Domingo-Domenech J., Pippa R., Tapia M., et al. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 2008, 112:53-62.
167. Scaife C.L., Kuang J., Wills J.C., et al. Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res 2002, 62:6870-6878.
168. Rundall B.K., Denlinger C.E., Jones D.R. Combined histone deacetylase and NF-kappaB inhibition sensitizes non-small cell lung cancer to cell death. Surgery 2004, 136:416-425.
169. Furuta H., Osawa K., Shin M., et al. Selective inhibition of NF-kappaB suppresses bone invasion by oral squamous cell carcinoma invivo. Int J Cancer 2012, 131:E625-E635.
170. Biswas D.K., Shi Q., Baily S., et al. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004, 101:10137-10142.
171. Zanotto-Filho A., Braganhol E., Schroder R., et al. NFkappaB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011, 81:412-424.
172. Lee H.R., Cheong H.J., Kim S.J., et al. Sulindac enhances arsenic trioxide-mediated apoptosis by inhibition of NF-kappaB in HCT116 colon cancer cells. Oncol Rep 2008, 20:41-47.
173. Ma Y., Wang J., Liu L., et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. Cancer Lett 2011, 301:75-84.
174. Mahieux R., Pise-Masison C., Gessain A., et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001, 98:3762-3769.
175. Woo S.Y., Lee M.Y., Jung Y.J., et al. Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol 2006, 23:231-243.
176. Mathieu J., Besancon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NF-kappa B activation in Ewing sarcoma cells. Int J Cancer 2006, 119:1723-1727.
177. Park M.J., Lee J.Y., Kwak H.J., et al. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. JCell Biochem 2005, 95:955-969.
178. Wei L.H., Lai K.P., Chen C.A., et al. Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB. Oncogene 2005, 24:390-398.
179. Zhou J.M., Zhu X.F., Pan Q.C., et al. Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. Int J Mol Med 2003, 12:955-959.
180. Salminen A., Lehtonen M., Paimela T., et al. Celastrol: molecular targets of thunder god vine. Biochem Biophys Res Commun 2010, 394:439-442.
181. Kannaiyan R., Hay H.S., Rajendran P., et al. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-kappaB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 2011, 164:1506-1521.
182. Chen M., Rose A.E., Doudican N., et al. Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res 2009, 7:1946-1953.
183. Dai Y., Desano J., Tang W., et al. Natural proteasome inhibitor celastrol suppresses androgen-independent prostate cancer progression by modulating apoptotic proteins and NF-kappaB. PLoS One 2010, 5:e14153.
184. Kim Y., Kang H., Jang S.W., et al. Celastrol inhibits breast cancer cell invasion via suppression of NF-kB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011, 28:175-184.
185. Pletz N., Schon M., Ziegelbauer K., et al. Doxorubicin-induced activation of NF-kappaB in melanoma cells is abrogated by inhibition of IKKbeta, but not by a novel IKKalpha inhibitor. Exp Dermatol 2012, 21:301-304.
186. Alameda J.P., Moreno-Maldonado R., Fernandez-Acenero M.J., et al. Increased IKKalpha expression in the basal layer of the epidermis of transgenic mice enhances the malignant potential of skin tumors. PLoS One 2011, 6:e21984.
187. Merkhofer E.C., Cogswell P., Baldwin A.S. Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 2010, 29:1238-1248.
188. Liu M., Lee D.F., Chen C.T., et al. IKKalpha activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell 2012, 45:171-184.
189. Mahato R., Qin B., Cheng K. Blocking IKKalpha expression inhibits prostate cancer invasiveness. Pharm Res 2011, 28:1357-1369.
190. Charalambous M.P., Lightfoot T., Speirs V., et al. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer 2009, 101:106-115.
191. Garber K. The second wave in kinase cancer drugs. Nat Biotechnol 2006, 24:127-130.
192. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. NEngl J Med 2008, 359:2195-2207.
193. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. NEngl J Med 2012, 367:1792-1802.
194. Denoyelle C., Vasse M., Korner M., et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an invitro study. Carcinogenesis 2001, 22:1139-1148.
195. Wang W., Collie-Duguid E., Cassidy J. Cerivastatin enhances the cytotoxicity of 5-fluorouracil on chemosensitive and resistant colorectal cancer cell lines. FEBS Lett 2002, 531:415-420.
196. Nubel T., Dippold W., Kaina B., et al. Ionizing radiation-induced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid. Carcinogenesis 2004, 25:1335-1344.
197. Katano H., Pesnicak L., Cohen J.I. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004, 101:4960-4965.
198. Ahn K.S., Sethi G., Aggarwal B.B. Simvastatin potentiates TNF-alpha-induced apoptosis through the down-regulation of NF-kappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. JImmunol 2007, 178:2507-2516.
199. Ghosh-Choudhury N., Mandal C.C., Ghosh Choudhury G. Simvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 2010, 22:749-758.
200. Han J.Y., Lee S.H., Yoo N.J., et al. Arandomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011, 17:1553-1560.
201. Han J.Y., Lim K.Y., Yu S.Y., et al. Aphase 2 study of irinotecan, cisplatin, and simvastatin for untreated extensive-disease small cell lung cancer. Cancer 2011, 117:2178-2185.
202. Konings I.R., van der Gaast A., van der Wijk L.J., et al. The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial. Eur J Cancer 2010, 46:3200-3204.
203. Schmidmaier R., Baumann P., Bumeder I., et al. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007, 79:240-243.
204. van der Spek E., Bloem A.C., Sinnige H.A., et al. High dose simvastatin does not reverse resistance to vincristine, adriamycin, and dexamethasone (VAD) in myeloma. Haematologica 2007, 92:e130-e131.
205. Batra R.K., Guttridge D.C., Brenner D.A., et al. IkappaBalpha gene transfer is cytotoxic to squamous-cell lung cancer cells and sensitizes them to tumor necrosis factor-alpha-mediated cell death. Am J Respir Cell Mol Biol 1999, 21:238-245.
206. Mukogawa T., Koyama F., Tachibana M., et al. Adenovirus-mediated gene transduction of truncated I kappa B alpha enhances radiosensitivity in human colon cancer cells. Cancer Sci 2003, 94:745-750.
207. Chen S., Fribley A., Wang C.Y. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor. JDent Res 2002, 81:98-102.
208. Weaver K.D., Yeyeodu S., Cusack J.C., et al. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. JNeurooncol 2003, 61:187-196.
209. Lee W.P., Tai D.I., Tsai S.L., et al. Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res 2003, 63:6229-6236.
210. Sanlioglu A.D., Dirice E., Aydin C., et al. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005, 5:54.
211. Sanlioglu A.D., Koksal I.T., Karacay B., et al. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006, 13:21-31.
212. Hortobagyi G.N., Ueno N.T., Xia W., et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. JClin Oncol 2001, 19:3422-3433.
213. Villaret D., Glisson B., Kenady D., et al. Amulticenter phase II study of tgDCC-E1A for the intratumoral treatment of patients with recurrent head and neck squamous cell carcinoma. Head Neck 2002, 24:661-669.
214. Ochiai T., Saito Y., Saitoh T., et al. Inhibition of IkappaB kinase beta restrains oncogenic proliferation of pancreatic cancer cells. JMed Dent Sci 2008, 55:49-59.
215. Diaz L.A., Messersmith W., Sokoll L., et al. TNF-blockade in patients with advanced hormone refractory prostate cancer. Invest New Drugs 2011, 29:192-194.
216. Larkin J.M., Ferguson T.R., Pickering L.M., et al. Aphase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma. Br J Cancer 2010, 103:1149-1153.
217. Madhusudan S., Foster M., Muthuramalingam S.R., et al. Aphase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:6528-6534.
218. Madhusudan S., Muthuramalingam S.R., Braybrooke J.P., et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. JClin Oncol 2005, 23:5950-5959.
219. Scott B.L., Ramakrishnan A., Storer B., et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 2010, 148:944-947.
220. Woyach J.A., Lin T.S., Lucas M.S., et al. Aphase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009, 23:912-918.
221. Jazirehi A.R., Huerta-Yepez S., Cheng G., et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005, 65:264-276.
222. Fizazi K., De Bono J.S., Flechon A., et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012, 48:85-93.
223. Rossi J.F., Negrier S., James N.D., et al. Aphase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 2010, 103:1154-1162.
224. Coward J., Kulbe H., Chakravarty P., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17:6083-6096.
225. Kanai M., Imaizumi A., Otsuka Y., et al. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol 2012, 69:65-70.
226. Steward W.P., Gescher A.J. Curcumin in cancer management: recent results of analogue design and clinical studies and desirable future research. Mol Nutr Food Res 2008, 52:1005-1009.
227. Szekeres T., Fritzer-Szekeres M., Saiko P., et al. Resveratrol and resveratrol analogues-structure-activity relationship. Pharm Res 2010, 27:1042-1048.
228. Johnson J.J., Mukhtar H. Curcumin for chemoprevention of colon cancer. Cancer Lett 2007, 255:170-181.
229. Mahabir S., Leitzmann M.F., Pietinen P., et al. Physical activity and renal cell cancer risk in a cohort of male smokers. Int J Cancer 2004, 108:600-605.
230. Kirkegaard H., Johnsen N.F., Christensen J., et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 2010, 341:c5504.
231. Romieu-Mourez R., Landesman-Bollag E., Seldin D.C., et al. Protein kinase CK2 promotes aberrant activation of nuclear factor-kappaB, transformed phenotype, and survival of breast cancer cells. Cancer Res 2002, 62:6770-6778.
232. Kato T., Delhase M., Hoffmann A., et al. CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 2003, 12:829-839.
233. Wu Z.H., Wong E.T., Shi Y., et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell 2010, 40:75-86.
234. Ling J., Kang Y., Zhao R., et al. KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 2012, 21:105-120.
235. Basseres D.S., Ebbs A., Levantini E., et al. Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 2010, 70:3537-3546.
236. Birkenkamp K.U., Geugien M., Schepers H., et al. Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004, 18:103-112.
237. Amma H., Naruse K., Ishiguro N., et al. Involvement of reactive oxygen species in cyclic stretch-induced NF-kappaB activation in human fibroblast cells. Br J Pharmacol 2005, 145:364-373.
238. Gloire G., Charlier E., Rahmouni S., et al. Restoration of SHIP-1 activity in human leukemic cells modifies NF-kappaB activation pathway and cellular survival upon oxidative stress. Oncogene 2006, 25:5485-5494.
239. Storz P., Doppler H., Toker A. Activation loop phosphorylation controls protein kinase D-dependent activation of nuclear factor kappaB. Mol Pharmacol 2004, 66:870-879.
240. Beraud C., Henzel W.J., Baeuerle P.A. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-kappaB activation. Proc Natl Acad Sci USA 1999, 96:429-434.
241. McAllister-Lucas L.M., Ruland J., Siu K., et al. CARMA3/Bcl10/MALT1-dependent NF-kappaB activation mediates angiotensin II-responsive inflammatory signaling in nonimmune cells. Proc Natl Acad Sci USA 2007, 104:139-144.
242. Kawauchi K., Araki K., Tobiume K., et al. Loss of p53 enhances catalytic activity of IKKbeta through O-linked beta-N-acetyl glucosamine modification. Proc Natl Acad Sci USA 2009, 106:3431-3436.
243. Rupec R.A., Baeuerle P.A. The genomic response of tumor cells to hypoxia andreoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B. Eur J Biochem 1995, 234:632-640.
244. Mezzanzanica D., Balladore E., Turatti F., et al. CD95-mediated apoptosis is impaired at receptor level by cellular FLICE-inhibitory protein (long form) in wild-type p53 human ovarian carcinoma. Clin Cancer Res 2004, 10:5202-5214.
245. Chen X., Kandasamy K., Srivastava R.K. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling. Cancer Res 2003, 63:1059-1066.
246. Bernard D., Quatannens B., Vandenbunder B., et al. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. JBiol Chem 2001, 276:27322-27328.
247. Wang C.Y., Mayo M.W., Korneluk R.G., et al. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281:1680-1683.
248. Lee R., Collins T. Nuclear factor-kappaB and cell survival: IAPs call for support. Circ Res 2001, 88:262-264.
249. Liston P., Fong W.G., Korneluk R.G. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003, 22:8568-8580.
250. Wright C.W., Duckett C.S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. JClin Invest 2005, 115:2673-2678.
251. Burstein E., Ganesh L., Dick R.D., et al. Anovel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J 2004, 23:244-254.
252. Kaur S., Wang F., Venkatraman M., et al. X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). JBiol Chem 2005, 280:38599-38608.
253. Tamm I., Wang Y., Sausville E., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998, 58:5315-5320.
254. Lee H.H., Dadgostar H., Cheng Q., et al. NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999, 96:9136-9141.
255. Tamatani M., Che Y.H., Matsuzaki H., et al. Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. JBiol Chem 1999, 274:8531-8538.
256. Wang C.Y., Guttridge D.C., Mayo M.W., et al. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 1999, 19:5923-5929.
257. Chen C., Edelstein L.C., Gelinas C. The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol 2000, 20:2687-2695.
258. Sun X.M., Bratton S.B., Butterworth M., et al. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. JBiol Chem 2002, 277:11345-11351.
259. Wadgaonkar R., Phelps K.M., Haque Z., et al. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. JBiol Chem 1999, 274:1879-1882.
260. Xu Y., Kiningham K.K., Devalaraja M.N., et al. An intronic NF-kappaB element is essential for induction of the human manganese superoxide dismutase gene by tumor necrosis factor-alpha and interleukin-1beta. DNA Cell Biol 1999, 18:709-722.
261. Pham C.G., Bubici C., Zazzeroni F., et al. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542.
262. Feuerhake F., Kutok J.L., Monti S., et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood 2005, 106:1392-1399.
263. Stoffel A., Chaurushiya M., Singh B., et al. Activation of NF-kappaB and inhibition of p53-mediated apoptosis by API2/mucosa-associated lymphoid tissue 1 fusions promote oncogenesis. Proc Natl Acad Sci USA 2004, 101:9079-9084.
264. Ohno H., Doi S., Yabumoto K., et al. Molecular characterization of the t(14;19)(q32;q13) translocation in chronic lymphocytic leukemia. Leukemia 1993, 7:2057-2063.
265. Cabannes E., Khan G., Aillet F., et al. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999, 18:3063-3070.
266. Annunziata C.M., Davis R.E., Demchenko Y., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
267. Keats J.J., Fonseca R., Chesi M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 2007, 12:131-144.
268. Migliazza A., Lombardi L., Rocchi M., et al. Heterogeneous chromosomal aberrations generate 3' truncations of the NFKB2/lyt-10 gene in lymphoid malignancies. Blood 1994, 84:3850-3860.
269. Boehm J.S., Zhao J.J., Yao J., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129:1065-1079.
270. Hutti J.E., Shen R.R., Abbott D.W., et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009, 34:461-472.
271. Hamdane M., David-Cordonnier M.H., D'Halluin J.C. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene 1997, 15:2267-2275.
272. Stirewalt D.L., Meshinchi S., Radich J.P. Molecular targets in acute myelogenous leukemia. Blood Rev 2003, 17:15-23.
273. Garkavtsev I., Kozin S.V., Chernova O., et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
274. Vitale-Cross L., Amornphimoltham P., Fisher G., et al. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 2004, 64:8804-8807.
275. Lu S.L., Herrington H., Reh D., et al. Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006, 20:1331-1342.
276. Molinolo A.A., Amornphimoltham P., Squarize C.H., et al. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009, 45:324-334.
277. Patel V., Rosenfeldt H.M., Lyons R., et al. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion. Carcinogenesis 2007, 28:1145-1152.
278. Romieu-Mourez R., Kim D.W., Shin S.M., et al. Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 2003, 23:5738-5754.
279. Benezra M., Chevallier N., Morrison D.J., et al. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. JBiol Chem 2003, 278:26333-26341.
280. Pianetti S., Arsura M., Romieu-Mourez R., et al. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 2001, 20:1287-1299.
281. Brose M.S., Volpe P., Feldman M., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
282. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
283. Stephens P., Hunter C., Bignell G., et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 2004, 431:525-526.
284. Davies H., Hunter C., Smith R., et al. Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 2005, 65:7591-7595.
285. Sher T., Dy G.K., Adjei A.A. Small cell lung cancer. Mayo Clin Proc 2008, 83:355-367.
286. Chow J.Y., Ban M., Wu H.L., et al. TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2010, 298:G275-G282.
287. Wilson W., Baldwin A.S. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008, 68:8156-8163.
288. Evertsson S., Sun X.F. Protein expression of NF-kappaB in human colorectal adenocarcinoma. Int J Mol Med 2002, 10:547-550.
289. Koumakpayi I.H., Le Page C., Mes-Masson A.M., et al. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer. Br J Cancer 2010, 102:1163-1173.
290. Dan H.C., Cooper M.J., Cogswell P.C., et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and raptor in association with IKK. Genes Dev 2008, 22:1490-1500.
291. Yang J., Splittgerber R., Yull F.E., et al. Conditional ablation of Ikkb inhibits melanoma tumor development in mice. JClin Invest 2010, 120:2563-2574.
292. Dhawan P., Su Y., Thu Y.M., et al. The lymphotoxin-beta receptor is an upstream activator of NF-kappaB-mediated transcription in melanoma cells. JBiol Chem 2008, 283:15399-15408.
293. Schwartz L., Guais A., Israel M., et al. Tumor regression with a combination of drugs interfering with the tumor metabolism: efficacy of hydroxycitrate, lipoic acid and capsaicin. Invest New Drugs 2013, 31(2):256-264.
294. Kang J.H., Kim C.S., Han I.S., et al. Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett 2007, 581:4389-4396.
295. Han S.S., Keum Y.S., Chun K.S., et al. Suppression of phorbol ester-induced NF-kappaB activation by capsaicin in cultured human promyelocytic leukemia cells. Arch Pharm Res 2002, 25:475-479.
296. Singh S., Natarajan K., Aggarwal B.B. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. JImmunol 1996, 157:4412-4420.
297. Joung E.J., Li M.H., Lee H.G., et al. Capsaicin induces heme oxygenase-1 expression in HepG2 cells via activation of PI3K-Nrf2 signaling: NAD(P)H:quinone oxidoreductase as a potential target. Antioxid Redox Signal 2007, 9:2087-2098.
298. Mukhopadhyay A., Basu N., Ghatak N., et al. Anti-inflammatory and irritant activities of curcumin analogues in rats. Agents Actions 1982, 12:508-515.
299. Sharma O.P. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol 1976, 25:1811-1812.
300. Lim G.P., Chu T., Yang F., et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. JNeurosci 2001, 21:8370-8377.
301. Arbiser J.L., Klauber N., Rohan R., et al. Curcumin is an invivo inhibitor of angiogenesis. Mol Med 1998, 4:376-383.
302. Ray S., Chattopadhyay N., Mitra A., et al. Curcumin exhibits antimetastatic properties by modulating integrin receptors, collagenase activity, and expression of Nm23 and E-cadherin. JEnviron Pathol Toxicol Oncol 2003, 22:49-58.
303. Rao C.V., Rivenson A., Simi B., et al. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55:259-266.
304. Tian F., Zhang C., Tian W., et al. Comparison of the effect of p65 siRNA and curcumin in promoting apoptosis in esophageal squamous cell carcinoma cells and in nude mice. Oncol Rep 2012, 28:232-240.
305. Chan M.M. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol 1995, 49:1551-1556.
306. Lee K.W., Kim J.H., Lee H.J., et al. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal 2005, 7:1612-1620.
307. Hatcher H., Planalp R., Cho J., et al. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 2008, 65:1631-1652.
308. Ren J., Fan C., Chen N., et al. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res 2011, 36:2352-2362.
309. Zhong M., Cheng G.F., Wang W.J., et al. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999, 6:79-84.
310. Zhang Q., Tang X., Lu Q.Y., et al. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1alpha and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 2005, 4:1465-1474.
311. Huderson A.C., Myers J.N., Niaz M.S., et al. Chemoprevention of benzo(a)pyrene-induced colon polyps in Apc(Min) mice by resveratrol. JNutr Biochem 2013, 24(4):713-724.
312. Liao P.C., Ng L.T., Lin L.T., et al. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. JMed Food 2010, 13:1415-1423.
313. Casanova F., Quarti J., da Costa D.C., et al. Resveratrol chemosensitizes breast cancer cells to melphalan by cell cycle arrest. JCell Biochem 2012, 113:2586-2596.
314. Qureshi A.A., Guan X.Q., Reis J.C., et al. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis 2012, 11:76.
315. Yeung F., Hoberg J.E., Ramsey C.S., et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004, 23:2369-2380.
316. Chen C.Y., Jang J.H., Li M.H., et al. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem Biophys Res Commun 2005, 331:993-1000.